8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 12, 2026·SEC
West Pharmaceutical Services, Inc.(WST)Earnings, Financials & Key Ratios
WST•NYSE
48.2× P/E·Price updated Jun 19, 2026
AboutWest Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.Show more
- Revenue$3.07B+6.3%
- EBITDA$742M-1.1%
- Net Income$494M+0.2%
- EPS (Diluted)6.80+1.6%
- Gross Margin35.89%+3.6%
- EBITDA Margin24.13%-6.9%
- Operating Margin20.09%-2.3%
- Net Margin16.06%-5.7%
- ROE16.85%-4.8%
WST Key Insights
West Pharmaceutical Services, Inc. (WST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Dividend Aristocrat: 33 years of consecutive increases
- ✓FCF machine: 15.3% free cash flow margin
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Good 3Y average ROE of 18.6%
- ✓Healthy 5Y average net margin of 19.4%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when WST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WST Price & Volume
West Pharmaceutical Services, Inc. (WST) stock price & volume — 10-year historical chart
Loading chart...
WST Growth Metrics
West Pharmaceutical Services, Inc. (WST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.2%
5 Years7.44%
3 Years2.13%
TTM11.22%
Profit CAGR
10 Years17.84%
5 Years7.36%
3 Years-5.55%
TTM16.16%
EPS CAGR
10 Years17.99%
5 Years8.27%
3 Years-4.18%
TTM17.58%
Return on Capital
10 Years20.19%
5 Years23.34%
3 Years20.05%
Last Year18.41%
WST Recent Earnings
West Pharmaceutical Services, Inc. (WST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 23, 2026Metric
Actual
Est
EPS
$2.13+26.8%
$1.68
Rev
$845M+8.3%
$780M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.04+11.5%
$1.83
Rev
$805M+1.3%
$795M
Q4 2025
Oct 23, 2025Metric
Actual
Est
EPS
$1.96+16.7%
$1.68
Rev
$804M+2.4%
$786M
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$1.84+21.9%
$1.51
Rev
$766M+5.5%
$726M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $2.13vs $1.68+26.8% | $845Mvs $780M+8.3% |
| Q1 2026 | Feb 12, 2026 | $2.04vs $1.83+11.5% | $805Mvs $795M+1.3% |
| Q4 2025 | Oct 23, 2025 | $1.96vs $1.68+16.7% | $804Mvs $786M+2.4% |
| Q3 2025 | Jul 24, 2025 | $1.84vs $1.51+21.9% | $766Mvs $726M+5.5% |
Based on last 12 quarters of dataView full earnings history →
WST Peer Comparison
West Pharmaceutical Services, Inc. (WST) competitors in Drug delivery and infusion consumables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATR | 7.75B | 120.32 | 20.46 | 5.42% | 9.98% | 18.64% | 0.56 | |
 GTLS | 9.96B | 207.99 | 630.27 | 2.49% | -0.63% | -0.78% | 1.11 | |
 AVTR | 6.54B | 9.58 | -12.28 | -3.41% | -8.42% | -9.59% | 0.71 | |
 AMCR | 18.98B | 41.08 | 25.68 | 10.04% | 3.06% | 5.8% | 1.28 | |
 SEE | 6.21B | 42.15 | 12.29 | -0.61% | 9.43% | 48.39% | 3.31 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare WST vs Peers
West Pharmaceutical Services, Inc. (WST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WST Income Statement
West Pharmaceutical Services, Inc. (WST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.6B | 1.72B | 1.84B | 2.15B | 2.83B | 2.89B | 2.95B | 2.89B | 3.07B | 3.22B |
Revenue Growth % | 6.04% | 7.36% | 7.31% | 16.44% | 31.86% | 1.94% | 2.27% | -1.98% | 6.26% | 11.22% |
Cost of Goods Sold | 1.09B | 1.17B | 1.23B | 1.38B | 1.66B | 1.75B | 1.82B | 1.89B | 1.97B | 2.05B |
COGS % of Revenue | 67.83% | 68.2% | 66.98% | 64.23% | 58.55% | 60.53% | 61.62% | 65.35% | 64.11% | - |
Gross Profit | 514.8M▲ 0% | 546.3M▲ 6.1% | 608.8M▲ 11.4% | 767.9M▲ 26.1% | 1.17B▲ 52.8% | 1.14B▼ 2.9% | 1.13B▼ 0.5% | 1B▼ 11.5% | 1.1B▲ 10.1% | 1.17B▲ 0% |
Gross Margin % | 32.17% | 31.8% | 33.02% | 35.77% | 41.45% | 39.47% | 38.38% | 34.65% | 35.89% | 36.24% |
Gross Profit Growth % | 2.75% | 6.12% | 11.44% | 26.13% | 52.81% | -2.94% | -0.54% | -11.52% | 10.09% | - |
Operating Expenses | 285.1M | 291.5M | 311.6M | 348.9M | 414.7M | 375.4M | 421.8M | 407.6M | 485.9M | 500.9M |
OpEx % of Revenue | 17.82% | 16.97% | 16.9% | 16.25% | 14.65% | 13.01% | 14.29% | 14.09% | 15.81% | - |
Selling, General & Admin | 246M | 262.9M | 272.7M | 302M | 361.9M | 316.9M | 353.4M | 338.5M | 393.1M | 404.6M |
SG&A % of Revenue | 15.37% | 15.3% | 14.79% | 14.07% | 12.78% | 10.98% | 11.98% | 11.7% | 12.79% | - |
Research & Development | 39.1M | 40.3M | 38.9M | 46.9M | 52.8M | 58.5M | 68.4M | 69.1M | 74.3M | 73.8M |
R&D % of Revenue | 2.44% | 2.35% | 2.11% | 2.18% | 1.87% | 2.03% | 2.32% | 2.39% | 2.42% | - |
Other Operating Expenses | 0 | -11.7M | 0 | 0 | 0 | 0 | 0 | 0 | 18.5M | 2M |
Operating Income | 229.7M▲ 0% | 254.8M▲ 10.9% | 297.2M▲ 16.6% | 419M▲ 41.0% | 758.7M▲ 81.1% | 763.5M▲ 0.6% | 710.9M▼ 6.9% | 594.6M▼ 16.4% | 617.4M▲ 3.8% | 665.6M▲ 0% |
Operating Margin % | 14.35% | 14.83% | 16.12% | 19.52% | 26.8% | 26.46% | 24.09% | 20.56% | 20.09% | 20.67% |
Operating Income Growth % | 6.59% | 10.93% | 16.64% | 40.98% | 81.07% | 0.63% | -6.89% | -16.36% | 3.83% | - |
EBITDA | 326.4M | 359.2M | 400.6M | 528.1M | 881M | 884.1M | 848.2M | 750M | 741.8M | 793.8M |
EBITDA Margin % | 20.4% | 20.91% | 21.73% | 24.6% | 31.12% | 30.64% | 28.74% | 25.93% | 24.13% | 24.65% |
EBITDA Growth % | 6.6% | 10.05% | 11.53% | 31.83% | 66.82% | 0.35% | -4.06% | -11.58% | -1.09% | 4.81% |
D&A (Non-Cash Add-back) | 96.7M | 104.4M | 103.4M | 109.1M | 122.3M | 120.6M | 137.3M | 155.4M | 124.4M | 131.4M |
EBIT | 229.5M | 248.8M | 299.8M | 409.8M | 757.4M | 687.5M | 706.8M | 588.4M | 599.2M | 667.6M |
Net Interest Income | -5.8M | -6M | -4.2M | -7.1M | -7.5M | -2.5M | 19.2M | 16.7M | 17.1M | 16.6M |
Interest Income | 1.3M | 2.1M | 3.8M | 1.4M | 1M | 5.1M | 28M | 19.6M | 17.7M | 16.8M |
Interest Expense | 7.1M | 8.1M | 8M | 8.5M | 8.5M | 7.6M | 8.8M | 2.9M | 600K | 200K |
Other Income/Expense | 1.9M | -6.5M | 3.5M | -300K | 10.3M | -62.9M | 4.8M | 5.6M | -2.1M | 15.9M |
Pretax Income | 231.6M▲ 0% | 248.3M▲ 7.2% | 300.7M▲ 21.1% | 418.7M▲ 39.2% | 769M▲ 83.7% | 700.6M▼ 8.9% | 715.7M▲ 2.2% | 600.2M▼ 16.1% | 615.3M▲ 2.5% | 681.5M▲ 0% |
Pretax Margin % | 14.47% | 14.45% | 16.31% | 19.5% | 27.17% | 24.28% | 24.25% | 20.75% | 20.02% | 21.16% |
Income Tax | 80.9M | 41.4M | 59M | 72.5M | 107.2M | 114.7M | 122.3M | 107.5M | 121.6M | 142.2M |
Effective Tax Rate % | 34.93% | 16.67% | 19.62% | 17.32% | 13.94% | 16.37% | 17.09% | 17.91% | 19.76% | 20.87% |
Net Income | 150.7M▲ 0% | 206.9M▲ 37.3% | 241.7M▲ 16.8% | 346.2M▲ 43.2% | 661.8M▲ 91.2% | 585.9M▼ 11.5% | 593.4M▲ 1.3% | 492.7M▼ 17.0% | 493.7M▲ 0.2% | 542.7M▲ 0% |
Net Margin % | 9.42% | 12.04% | 13.11% | 16.13% | 23.38% | 20.3% | 20.11% | 17.03% | 16.06% | 16.85% |
Net Income Growth % | 4.94% | 37.29% | 16.82% | 43.24% | 91.16% | -11.47% | 1.28% | -16.97% | 0.2% | 16.16% |
Net Income (Continuing) | 150.7M | 206.9M | 241.7M | 346.2M | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M | 539.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.99▲ 0% | 2.74▲ 37.7% | 3.21▲ 17.2% | 4.57▲ 42.4% | 8.67▲ 89.7% | 7.73▼ 10.8% | 7.88▲ 1.9% | 6.69▼ 15.1% | 6.80▲ 1.6% | 7.50▲ 0% |
EPS Growth % | 4.19% | 37.69% | 17.15% | 42.37% | 89.72% | -10.84% | 1.94% | -15.1% | 1.64% | 17.58% |
EPS (Basic) | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 | 6.75 | 6.83 | - |
Diluted Shares Outstanding | 75.8M | 75.4M | 75.4M | 75.8M | 76.3M | 75.8M | 75.3M | 73.7M | 72.7M | 72.4M |
Basic Shares Outstanding | 73.9M | 73.9M | 74M | 73.9M | 74.4M | 74.4M | 74.3M | 73M | 72.3M | 72M |
Dividend Payout Ratio | 25.95% | 20.35% | 18.66% | 13.89% | 7.72% | 9.23% | 9.61% | 12% | 12.4% | - |
WST Balance Sheet
West Pharmaceutical Services, Inc. (WST) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 743.5M | 894.4M | 1.06B | 1.37B | 1.74B | 1.92B | 1.94B | 1.54B | 1.98B | 1.83B |
Cash & Short-Term Investments | 235.9M | 337.4M | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 484.6M | 791.3M | 521.4M |
Cash Only | 235.9M | 337.4M | 439.1M | 615.5M | 762.6M | 894.3M | 853.9M | 484.6M | 791.3M | 521.4M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 253.2M | 288.2M | 319.3M | 385.3M | 489M | 507.4M | 512M | 552.5M | 574.4M | 685.6M |
Days Sales Outstanding | 57.75 | 61.23 | 63.22 | 65.51 | 63.05 | 64.18 | 63.33 | 69.71 | 68.21 | 69.91 |
Inventory | 215.2M | 214.5M | 235.7M | 321.3M | 378.4M | 414.8M | 434.7M | 377M | 443.9M | 452.6M |
Days Inventory Outstanding | 72.37 | 66.82 | 69.67 | 85.06 | 83.34 | 86.68 | 87.26 | 72.79 | 82.23 | 78.02 |
Other Current Assets | 39.2M | 54.3M | 64.6M | 51.6M | 112M | 103M | 135.8M | 124M | 168.6M | 167.2M |
Total Non-Current Assets | 1.12B | 1.08B | 1.28B | 1.42B | 1.57B | 1.7B | 1.89B | 2.11B | 2.29B | 2.28B |
Property, Plant & Equipment | 855M | 822M | 909.4M | 1.01B | 1.13B | 1.26B | 1.51B | 1.69B | 0 | 3.33B |
Fixed Asset Turnover | 1.87x | 2.09x | 2.03x | 2.12x | 2.51x | 2.29x | 1.95x | 1.72x | - | 1.46x |
Goodwill | 107.7M | 105.8M | 107.8M | 111.1M | 109.9M | 107.3M | 108.5M | 106.1M | 109.9M | 109.2M |
Intangible Assets | 21.7M | 20.4M | 29.8M | 30.5M | 23M | 18.4M | 15.1M | 10.8M | 7.7M | 7M |
Long-Term Investments | 85.8M | 91.2M | 192.7M | 214.7M | 207.7M | 204.9M | 210M | 202.1M | 212.3M | 867.1M |
Other Non-Current Assets | 23.4M | 20.5M | 29M | 36.3M | 55.9M | 38.4M | 21.3M | 74.3M | 1.96B | -1.44B |
Total Assets | 1.86B▲ 0% | 1.59B▼ 14.5% | 2.34B▲ 47.0% | 2.79B▲ 19.3% | 3.31B▲ 18.6% | 3.62B▲ 9.1% | 3.83B▲ 5.9% | 3.64B▼ 4.9% | 4.27B▲ 17.2% | 4.11B▲ 0% |
Asset Turnover | 0.86x | 1.08x | 0.79x | 0.77x | 0.85x | 0.80x | 0.77x | 0.79x | 0.72x | 0.78x |
Asset Growth % | 8.51% | -14.52% | 47.04% | 19.32% | 18.61% | 9.14% | 5.88% | -4.86% | 17.2% | 55.78% |
Total Current Liabilities | 279.5M | 283.7M | 341.6M | 503.4M | 594.1M | 519M | 671.8M | 550.4M | 654.9M | 674M |
Accounts Payable | 138.1M | 130.4M | 156.8M | 213.1M | 232.2M | 215.4M | 242.4M | 239.3M | 253.7M | 252.3M |
Days Payables Outstanding | 46.44 | 40.62 | 46.35 | 56.41 | 51.14 | 45.01 | 48.66 | 46.2 | 47 | 44.47 |
Short-Term Debt | 0 | 100K | 2.3M | 2.3M | 44.2M | 2.2M | 134M | 18.8M | 22.7M | 21.4M |
Deferred Revenue (Current) | 18.4M | 25.5M | 27.5M | 51M | 48.7M | 57.3M | 41.7M | 49.6M | 0 | 0 |
Other Current Liabilities | 22.7M | 22.6M | 28.8M | 49.9M | 45.1M | 54M | 54.2M | 100.5M | 214.5M | 400.3M |
Current Ratio | 2.66x | 3.15x | 3.10x | 2.73x | 2.93x | 3.70x | 2.88x | 2.79x | 3.02x | 2.71x |
Quick Ratio | 1.89x | 2.40x | 2.41x | 2.09x | 2.30x | 2.90x | 2.24x | 2.11x | 2.34x | 2.04x |
Cash Conversion Cycle | 83.68 | 87.43 | 86.54 | 94.16 | 95.25 | 105.85 | 101.93 | 96.3 | 103.44 | 103.46 |
Total Non-Current Liabilities | 303.4M | 298.9M | 426.6M | 435.9M | 384.3M | 412.9M | 276.7M | 410.7M | 439.1M | 445.4M |
Long-Term Debt | 197M | 196M | 255M | 252.9M | 208.8M | 206.7M | 72.8M | 202.6M | 298.4M | 294.8M |
Capital Lease Obligations | 0 | 0 | 62.4M | 60.4M | 63M | 93M | 84.5M | 83.9M | 95.6M | 248.9M |
Deferred Tax Liabilities | 10.4M | 13.1M | 15.5M | 10.4M | 4.9M | 14.3M | 12.7M | 20.5M | 23M | 68.5M |
Other Non-Current Liabilities | 96M | 89.8M | 93.7M | 112.2M | 107.6M | 98.9M | 106.7M | 103.7M | 22.1M | 127.9M |
Total Liabilities | 582.9M | 582.6M | 768.2M | 939.3M | 978.4M | 931.9M | 948.5M | 961.1M | 1.09B | 1.12B |
Total Debt | 197M | 196.1M | 329.3M | 325.7M | 325.3M | 317.9M | 309M | 305.3M | 416.7M | 316.2M |
Net Debt | -38.9M | -141.3M | -109.8M | -289.8M | -437.3M | -576.4M | -544.9M | -179.3M | -374.6M | -205.2M |
Debt / Equity | 0.15x | 0.14x | 0.21x | 0.18x | 0.14x | 0.12x | 0.11x | 0.11x | 0.13x | 0.11x |
Debt / EBITDA | 0.60x | 0.55x | 0.82x | 0.62x | 0.37x | 0.36x | 0.36x | 0.41x | 0.56x | 0.40x |
Net Debt / EBITDA | -0.12x | -0.39x | -0.27x | -0.55x | -0.50x | -0.65x | -0.64x | -0.24x | -0.50x | -0.26x |
Interest Coverage | 32.32x | 30.72x | 37.48x | 48.21x | 89.11x | 90.46x | 80.32x | 202.90x | 998.67x | 3338.00x |
Total Equity | 1.28B▲ 0% | 1.4B▲ 9.1% | 1.57B▲ 12.7% | 1.85B▲ 17.9% | 2.34B▲ 25.9% | 2.68B▲ 15.0% | 2.88B▲ 7.3% | 2.68B▼ 6.9% | 3.18B▲ 18.4% | 2.99B▲ 0% |
Equity Growth % | 14.53% | 9.09% | 12.67% | 17.88% | 25.93% | 14.97% | 7.3% | -6.9% | 18.41% | 54.41% |
Book Value per Share | 16.89 | 18.52 | 20.86 | 24.47 | 30.61 | 35.42 | 38.26 | 36.39 | 43.69 | 41.30 |
Total Shareholders' Equity | 1.28B | 1.4B | 1.57B | 1.85B | 2.34B | 2.68B | 2.88B | 2.68B | 3.18B | 2.99B |
Common Stock | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M |
Retained Earnings | 1.18B | 1.35B | 1.55B | 1.85B | 2.46B | 2.99B | 3.52B | 3.96B | 4.37B | 4.48B |
Treasury Stock | -109.1M | -103.7M | -118.1M | -167.7M | -229.5M | -370.9M | -637.6M | -1.06B | -1.11B | -1.38B |
Accumulated OCI | -117.3M | -154.2M | -149.6M | -110.6M | -159.6M | -183M | -143.8M | -258.1M | -105.5M | -125.2M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WST Cash Flow Statement
West Pharmaceutical Services, Inc. (WST) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 263.3M | 288.6M | 367.2M | 472.5M | 584M | 724M | 776.5M | 653.4M | 754.8M | 715.3M |
Operating CF Margin % | 16.45% | 16.8% | 19.92% | 22.01% | 20.63% | 25.09% | 26.31% | 22.59% | 24.56% | - |
Operating CF Growth % | 20.01% | 9.61% | 27.23% | 28.68% | 23.6% | 23.97% | 7.25% | -15.85% | 15.52% | 18.39% |
Net Income | 150.7M | 206.9M | 241.7M | 346.2M | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M | 542.7M |
Depreciation & Amortization | 96.7M | 104.4M | 103.4M | 109.1M | 122.3M | 120.6M | 137.3M | 155.4M | 168.6M | 175.4M |
Stock-Based Compensation | 16.1M | 15.1M | 24.4M | 34M | 37.5M | 23.7M | 23.3M | 18.7M | 23.8M | 29.1M |
Deferred Taxes | 41.7M | 900K | 15.3M | -5.8M | -42.9M | -30.8M | 37.5M | 0 | -13.7M | 0 |
Other Non-Cash Items | -500K | -10.4M | -3.2M | -700K | -900K | 36.1M | 5.4M | -16.3M | 2.6M | -97.7M |
Working Capital Changes | -41.4M | -28.3M | -14.4M | -10.3M | -193.8M | -15M | -20.4M | 2.9M | 79.8M | 65.8M |
Change in Receivables | -39.7M | -43.8M | -33.3M | -46.6M | -123.5M | -35.6M | 4M | -58.8M | 6.9M | 6.9M |
Change in Inventory | -3.6M | -7M | -18.6M | -73.7M | -86.5M | -49.8M | -13.5M | 42M | -62.8M | -62.8M |
Change in Payables | 12.6M | 400K | 25.3M | 36.6M | 16.8M | -2.8M | 4.4M | 2.9M | 17.9M | 0 |
Cash from Investing | -133.6M | -100.8M | -228M | -179.5M | -253.1M | -288.2M | -368.7M | -378.7M | -285.9M | -257.3M |
Capital Expenditures | -130.8M | -104.7M | -126.4M | -174.4M | -253.4M | -284.6M | -362M | -377M | -285.9M | -257.3M |
CapEx % of Revenue | 8.17% | 6.09% | 6.86% | 8.12% | 8.95% | 9.86% | 12.27% | 13.03% | 9.3% | 7.99% |
Acquisitions | -6M | 0 | -104M | 0 | -2.2M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.2M | 3.9M | 2.4M | -5.1M | 2.5M | -3.6M | -6.7M | -1.7M | 0 | 0 |
Cash from Financing | -109M | -80.7M | -36.8M | -137.1M | -168.1M | -293.6M | -459.6M | -622.6M | -185.1M | -346.8M |
Debt Issued (Net) | -34.9M | -100K | 62.1M | -2.3M | -2.2M | -44.3M | -2.3M | -27.6M | -1.1M | -900K |
Equity Issued (Net) | -74.4M | -70.8M | -85.3M | -121.4M | -151.9M | -222.2M | -451.2M | -566.6M | -115.8M | 3.2M |
Dividends Paid | -39.1M | -42.1M | -45.1M | -48.1M | -51.1M | -54.1M | -57M | -59.1M | -61.2M | -61.8M |
Share Repurchases | -74.4M | -70.8M | -85.3M | -121.4M | -151.9M | -222.2M | -451.2M | -566.6M | -134M | -800K |
Other Financing | 39.4M | 32.3M | 31.5M | 34.7M | 37.1M | 27M | 50.9M | 30.7M | -7M | -287.3M |
Net Change in Cash | 32.9M▲ 0% | 101.5M▲ 208.5% | 101.7M▲ 0.2% | 176.4M▲ 73.5% | 147.1M▼ 16.6% | 131.7M▼ 10.5% | -40.4M▼ 130.7% | -369.3M▼ 814.1% | 306.7M▲ 183.0% | 117.2M▲ 0% |
Free Cash Flow | 132.5M▲ 0% | 183.9M▲ 38.8% | 240.8M▲ 30.9% | 298.1M▲ 23.8% | 330.6M▲ 10.9% | 439.4M▲ 32.9% | 414.5M▼ 5.7% | 276.4M▼ 33.3% | 468.9M▲ 69.6% | 458M▲ 0% |
FCF Margin % | 8.28% | 10.7% | 13.06% | 13.89% | 11.68% | 15.23% | 14.05% | 9.56% | 15.26% | 14.22% |
FCF Growth % | 169.31% | 38.79% | 30.94% | 23.8% | 10.9% | 32.91% | -5.67% | -33.32% | 69.65% | 49.23% |
FCF per Share | 1.75 | 2.44 | 3.19 | 3.93 | 4.33 | 5.80 | 5.50 | 3.75 | 6.45 | 6.33 |
FCF Conversion (FCF/Net Income) | 1.75x | 1.39x | 1.52x | 1.36x | 0.88x | 1.24x | 1.31x | 1.33x | 1.53x | 0.84x |
Interest Paid | 8M | 8.4M | 8.6M | 8.1M | 8M | 6.6M | 6M | 500K | 0 | 300K |
Taxes Paid | 31M | 42M | 47.5M | 48.4M | 171.8M | 109.7M | 90.8M | 71.4M | 0 | 0 |
WST Key Ratios
West Pharmaceutical Services, Inc. (WST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 12.57% | 15.46% | 16.28% | 20.2% | 31.59% | 23.34% | 21.32% | 17.71% | 16.85% | 17.87% |
Return on Invested Capital (ROIC) | 14.45% | 15.31% | 16.4% | 20.76% | 32.87% | 28.58% | 23.99% | 18.43% | 17.46% | 18.26% |
Gross Margin | 32.17% | 31.8% | 33.02% | 35.77% | 41.45% | 39.47% | 38.38% | 34.65% | 35.89% | 36.24% |
Net Margin | 9.42% | 12.04% | 13.11% | 16.13% | 23.38% | 20.3% | 20.11% | 17.03% | 16.06% | 16.85% |
Debt / Equity | 0.15x | 0.14x | 0.21x | 0.18x | 0.14x | 0.12x | 0.11x | 0.11x | 0.13x | 0.11x |
Interest Coverage | 32.32x | 30.72x | 37.48x | 48.21x | 89.11x | 90.46x | 80.32x | 202.90x | 998.67x | 3338.00x |
FCF Conversion | 1.75x | 1.39x | 1.52x | 1.36x | 0.88x | 1.24x | 1.31x | 1.33x | 1.53x | 0.84x |
Revenue Growth | 6.04% | 7.36% | 7.31% | 16.44% | 31.86% | 1.94% | 2.27% | -1.98% | 6.26% | 11.22% |
Related:WST Dividend History·WST Revenue History·WST Price History·WST P/E History·WST Financial Ratios·WST Institutional Holders
WST SEC Filings & Documents
West Pharmaceutical Services, Inc. (WST) SEC filings — annual & quarterly reports (10-K, 10-Q)
WST Frequently Asked Questions
West Pharmaceutical Services, Inc. (WST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
West Pharmaceutical Services, Inc. (WST) reported $3.22B in revenue for fiscal year 2025. This represents a 602% increase from $458.8M in 1996.
West Pharmaceutical Services, Inc. (WST) grew revenue by 6.3% over the past year. This is steady growth.
Yes, West Pharmaceutical Services, Inc. (WST) is profitable, generating $542.7M in net income for fiscal year 2025 (16.1% net margin).
Dividend & Returns
Yes, West Pharmaceutical Services, Inc. (WST) pays a dividend with a yield of 0.26%. This makes it attractive for income-focused investors.
West Pharmaceutical Services, Inc. (WST) has a return on equity (ROE) of 16.9%. This is reasonable for most industries.
West Pharmaceutical Services, Inc. (WST) generated $458.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.